Ozempic, Other Drugs Selected for Maryland Pricing Review (1)

March 12, 2024, 6:29 PM UTCUpdated: March 12, 2024, 9:14 PM UTC

Maryland’s prescription drug affordability review board is looking at whether to set health plan payment limits for the blockbuster diabetes drug Ozempic, along with other products from companies that have sued the Biden administration over Medicare price negotiations.

Novo Nordisk A/S‘s Ozempic, approved to lower blood sugar levels and reduce the risk of heart attack and other conditions in adults with Type 2 diabetes, is one of eight drugs the Maryland Prescription Drug Affordability Board plans to send to the state’s stakeholder council for further affordability review, according to an agenda for the board’s March 25 meeting.

Maryland’s PDAB, ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.